David Ege - Seres Therapeutics Executive Officer
| MCRB Stock | USD 0.73 0.08 9.65% |
Executive
David Ege is Executive Officer of Seres Therapeutics
| Age | 49 |
| Address | 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 |
| Phone | 617 945 9626 |
| Web | https://www.serestherapeutics.com |
David Ege Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Ege against Seres Therapeutics stock is an integral part of due diligence when investing in Seres Therapeutics. David Ege insider activity provides valuable insight into whether Seres Therapeutics is net buyers or sellers over its current business cycle. Note, Seres Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seres Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Ege over three months ago Disposition of 1128 shares by David Ege of Seres Therapeutics at 0.84 subject to Rule 16b-3 |
Seres Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.097) % which means that it has lost $0.097 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.5628) %, meaning that it created substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.66, whereas Return On Tangible Assets are forecasted to decline to (0.33). At present, Seres Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 53.5 M, whereas Total Assets are forecasted to decline to about 225.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| RN MBA | Transcode Therapeutics | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| David Brady | Zura Bio Limited | N/A | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Verender Badial | Zura Bio Limited | 52 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
Management Performance
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 |
Seres Therapeutics Leadership Team
Elected by the shareholders, the Seres Therapeutics' board of directors comprises two types of representatives: Seres Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seres. The board's role is to monitor Seres Therapeutics' management team and ensure that shareholders' interests are well served. Seres Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seres Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff York, VP HR | ||
| Carlo Tanzi, Head of Investor Relations and Corporate Communications | ||
| SPHR SHRMSCP, Executive Officer | ||
| RPh Young, Executive Officer | ||
| Kristin Ainsworth, Sr Communications | ||
| JD Esq, Executive Officer | ||
| David Ege, Executive Officer | ||
| Lisa MD, Executive Officer | ||
| Marella CPA, Executive CFO | ||
| Caroline Holda, Assistant Counsel | ||
| Matthew Henn, Chief Scientific Officer | ||
| Eric MBA, CEO President | ||
| David MBA, CFO VP | ||
| Marella Thorell, Executive CFO |
Seres Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seres Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.097 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 165.75 M | ||||
| Shares Outstanding | 170.74 M | ||||
| Shares Owned By Insiders | 13.19 % | ||||
| Shares Owned By Institutions | 37.55 % | ||||
| Number Of Shares Shorted | 17.85 M | ||||
| Price To Earning | (4.04) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.